Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

Xiaoge BEI; Jinjun CHEN; Beiling LI

doi:10.3969/j.issn.1001-5256.2021.09.041

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2206-2209

PDF( 1991 KB)

Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.09.041

Liver Disease Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Research funding:

National Science and Technology Major Project (2018ZX10723203);

National Science and Technology Major Project (2018ZX10302206);

National Key Research and Development Program of China (2017YFC0908100);

Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131);

Clinical Research Program of Nanfang Hospital (2018CR037);

Clinical Research Program of Nanfang Hospital (2020CR026);

Clinical Research Program of Nanfang Hospital, Southern Medical University (LC2019ZD006)

Received Date: 2021-02-03
Accepted Date: 2021-05-07
Published Date: 2021-09-20

Abstract

Abstract

Due to persistent systemic inflammation and immunosuppressive conditions, patients with liver cirrhosis are susceptible to bacterial infection, which may progress to sepsis without proper control. Early effective antibiotic therapy is the key to improving the prognosis of patients with sepsis. This article briefly describes the pathophysiological mechanism of sepsis in patients with liver cirrhosis and the current status of the diagnosis and treatment of sepsis, and it is pointed out that metagenomic next-generation sequencing can be used to guide effective antibacterial treatment of sepsis.
- Liver Cirrhosis,
- Sepsis,
- Metagenomics,
- Sequence Analysis

FullText(HTML)

References(41)

References

[1]	FERNÁNDEZ J, PRADO V, TREBICKA J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe[J]. J Hepatol, 2019, 70(3): 398-411. DOI: 10.1016/j.jhep.2018.10.027.
[2]	FERNÁNDEZ J, ACEVEDO J, CASTRO M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study[J]. Hepatology, 2012, 55(5): 1551-1561. DOI: 10.1002/hep.25532.
[3]	ARVANITI V, D'AMICO G, FEDE G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256.e1-e5. DOI: 10.1053/j.gastro.2010.06.019.
[4]	QAZI SA, STOLL BJ. Neonatal sepsis: A major global public health challenge[J]. Pediatr Infect Dis J, 2009, 28(1 Suppl): s1-s2. DOI: 10.1097/INF.0b013e31819587a9.
[5]	ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
[6]	CAMPBELL KA, TRIVEDI HD, CHOPRA S. Infections in cirrhosis: A guide for the clinician[J]. Am J Med, 2021, 134(6): 727-734. DOI: 10.1016/j.amjmed.2021.01.015.
[7]	LEBOSSÉ F, GUDD C, TUNC E, et al. CD8⁺T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction[J]. EBio Medicine, 2019, 49: 258-268. DOI: 10.1016/j.ebiom.2019.10.011.
[8]	BERNSMEIER C, POP OT, SINGANAYAGAM A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J]. Gastroenterology, 2015, 148(3): 603-615.e14. DOI: 10.1053/j.gastro.2014.11.045.
[9]	BOUSSIF A, ROLAS L, WEISS E, et al. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis[J]. J Hepatol, 2016, 64(5): 1041-1048. DOI: 10.1016/j.jhep.2015.12.005.
[10]	LI BL, GAO YH, WANG XB, et al. Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study[J]. Liver Int, 2020, 40(6): 1447-1456. DOI: 10.1111/liv.14418.
[11]	ENGELMANN C, BECKER C, BOLDT A, et al. Ascites' neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation[J]. Sci Rep, 2016, 6: 37926. DOI: 10.1038/srep37926.
[12]	NICOLETTI A, PONZIANI FR, BIOLATO M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World J Gastroenterol, 2019, 25(33): 4814-4834. DOI: 10.3748/wjg.v25.i33.4814.
[13]	OKUMURA R, TAKEDA K. Maintenance of intestinal homeostasis by mucosal barriers[J]. Inflamm Regen, 2018, 38: 5. DOI: 10.1186/s41232-018-0063-z.
[14]	DI PASCOLI M, SACERDOTI D, PONTISSO P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2): 92-99. DOI: 10.1159/000462974.
[15]	WANG L, FOUTS DE, STÄRKEL P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation[J]. Cell Host Microbe, 2016, 19(2): 227-239. DOI: 10.1016/j.chom.2016.01.003.
[16]	GHOSH G, JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol, 2019, 9(2): 257-267. DOI: 10.1016/j.jceh.2018.08.006.
[17]	LAPIDOT Y, AMIR A, NOSENKO R, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma[J]. mSystems, 2020, 5(3). DOI: 10.1128/mSystems.00153-20.
[18]	DEL CAMPO JA, GALLEGO P, GRANDE L. Role of inflammatory response in liver diseases: Therapeutic strategies[J]. World J Hepatol, 2018, 10(1): 1-7. DOI: 10.4254/wjh.v10.i1.1.
[19]	ELCHANINOV AV, FATKHUDINOV TK, VISHNYAKOVA PA, et al. Phenotypical and functional polymorphism of liver resident macrophages[J]. Cells, 2019, 8(9): 1032. DOI: 10.3390/cells8091032.
[20]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
[21]	SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
[22]	VARON J, BARON RM. A current appraisal of evidence for the approach to sepsis and septic shock[J]. Ther Adv Infect Dis, 2019, 6: 2049936119856517. DOI: 10.1177/2049936119856517.
[23]	LIU ZC, YANG XS. Nutritional support treatment strategies for sepsis[J]. Chin J Dig Surg, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006. 刘正才, 杨西胜. 脓毒症营养支持治疗策略[J]. 中华消化外科杂志, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006.
[24]	SEYMOUR CW, GESTEN F, PRESCOTT HC, et al. Time to treatment and mortality during mandated emergency care for sepsis[J]. N Engl J Med, 2017, 376(23): 2235-2244. DOI: 10.1056/NEJMoa1703058.
[25]	WHILES BB, DEIS AS, SIMPSON SQ. Increased time to initial antimicrobial administration is associated with progression to septic shock in severe sepsis patients[J]. Crit Care Med, 2017, 45(4): 623-629. DOI: 10.1097/CCM.0000000000002262.
[26]	RHODES A, EVANS LE, ALHAZZANI W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 45(3): 486-552. DOI: 10.1097/CCM.0000000000002255.
[27]	BARTOLETTI M, GIANNELLA M, LEWIS R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients[J]. Clin Microbiol Infect, 2018, 24(5): 546. e1-546. e8. DOI: 10.1016/j.cmi.2017.08.001.
[28]	PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380.e10. DOI: 10.1053/j.gastro.2018.12.005.
[29]	HARBARTH S, GARBINO J, PUGIN J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis[J]. Am J Med, 2003, 115(7): 529-535. DOI: 10.1016/j.amjmed.2003.07.005.
[30]	KUMAR A, ELLIS P, ARABI Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock[J]. Chest, 2009, 136(5): 1237-1248. DOI: 10.1378/chest.09-0087.
[31]	SINGER M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification?[J]. Am J Respir Crit Care Med, 2017, 196(7): 800-802. DOI: 10.1164/rccm.201703-0621ED.
[32]	ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
[33]	LIPPI G. Sepsis biomarkers: Past, present and future[J]. Clin Chem Lab Med, 2019, 57(9): 1281-1283. DOI: 10.1515/cclm-2018-1347.
[34]	KIM H, HUR M, MOON HW, et al. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis[J]. Ann Intensive Care, 2017, 7(1): 27. DOI: 10.1186/s13613-017-0252-y.
[35]	PALACIOS G, DRUCE J, DU L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases[J]. N Engl J Med, 2008, 358(10): 991-998. DOI: 10.1056/NEJMoa073785.
[36]	XU B, LIU L, HUANG X, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: Discovery of a new bunyavirus[J]. PLoS Pathog, 2011, 7(11): e1002369. DOI: 10.1371/journal.ppat.1002369.
[37]	LANGLEY RJ, WONG HR. Early diagnosis of sepsis: Is an integrated omics approach the way forward?[J]. Mol Diagn Ther, 2017, 21(5): 525-537. DOI: 10.1007/s40291-017-0282-z.
[38]	ROZO M, SCHULLY KL, PHILIPSON C, et al. An observational study of sepsis in takeo province cambodia: An in-depth examination of pathogens causing severe infections[J]. PLoS Negl Trop Dis, 2020, 14(8): e0008381. DOI: 10.1371/journal.pntd.0008381.
[39]	GRUMAZ S, GRUMAZ C, VAINSHTEIN Y, et al. Enhanced performance of next-generation sequencing diagnostics compared with standard of care microbiological diagnostics in patients suffering from septic shock[J]. Crit Care Med, 2019, 47(5): e394- e402. DOI: 10.1097/CCM.0000000000003658.
[40]	GRUMAZ S, STEVENS P, GRUMAZ C, et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med, 2016, 8(1): 73. DOI: 10.1186/s13073-016-0326-8.
[41]	GRENINGER AL. The challenge of diagnostic metagenomics[J]. Expert Rev Mol Diagn, 2018, 18(7): 605-615. DOI: 10.1080/14737159.2018.1487292.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (492) PDF downloads(45)

Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.09.041

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.09.041

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content